ARTICLE SUMMARY:
Start-ups Cardiawave, SonoMotion, and Openwater each put their own spin on a therapeutic modality that has become a hot topic.
With an excellent track record in safety and a range of uses, focused ultrasound has become fertile ground for medical device innovation as of late, particularly with the high-profile sale of ultrasonic intravascular lithotripsy company Shockwave Medical to Johnson & Johnson for $13.1 billion. (See “Insiders Tell the Shockwave Story,” MedTech Strategist, September 24, 2025.) No longer just an imaging modality, ultrasound waves, when focused, can have a remarkable impact on cells, tissues, and mineral deposits in the body without any physical contact with instruments. Three start-up companies, Cardiawave, SonoMotion, and Openwater, are pushing the boundaries of focused ultrasound technology in three distinct directions.
